Endologix Stock Price, News & Analysis (NASDAQ:ELGX)

$5.25 0.05 (0.96 %)
(As of 12/18/2017 01:58 AM ET)
Previous Close$5.20
Today's Range$5.05 - $5.36
52-Week Range$4.08 - $7.66
Volume930,300 shs
Average Volume1.17 million shs
Market Capitalization$438.13 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72

About Endologix (NASDAQ:ELGX)

Endologix logoEndologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices & Implants
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Debt-to-Equity Ratio2.61%
Current Ratio2.90%
Quick Ratio2.11%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$192.93 million
Price / Sales2.27
Cash FlowN/A
Price / CashN/A
Book Value$1.36 per share
Price / Book3.86

Profitability

Trailing EPS($0.93)
Net Income$-154,670,000.00
Net Margins-41.60%
Return on Equity-52.18%
Return on Assets-13.70%

Miscellaneous

Employees782
Outstanding Shares83,450,000

Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) issued its quarterly earnings results on Tuesday, August, 2nd. The medical instruments supplier reported ($0.20) EPS for the quarter, hitting analysts' consensus estimates of ($0.20). The medical instruments supplier earned $51 million during the quarter, compared to analysts' expectations of $46.30 million. Endologix had a negative return on equity of 52.18% and a negative net margin of 41.60%. The business's quarterly revenue was up 29.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.18) earnings per share. View Endologix's Earnings History.

When will Endologix make its next earnings announcement?

Endologix is scheduled to release their next quarterly earnings announcement on Tuesday, February, 20th 2018. View Earnings Estimates for Endologix.

Where is Endologix's stock going? Where will Endologix's stock price be in 2017?

8 analysts have issued 1-year target prices for Endologix's shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate Endologix's stock price to reach $5.36 in the next twelve months. View Analyst Ratings for Endologix.

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:

  • 1. Canaccord Genuity analysts commented, "Alimera reported 2Q17 Iluvien US sales of $8.1M which was above our estimate of." (8/4/2017)
  • 2. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (7/25/2017)

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:

  • Daniel T. Lemaitre, Chairman of the Board (Age 63)
  • Robert D. Mitchell, President (Age 55)
  • John D. McDermott, Chief Executive Officer, Director (Age 57)
  • Vaseem Mahboob, Chief Financial Officer, Corporate Secretary (Age 48)
  • John Onopchenko, Chief Operating Officer (Age 59)
  • Michael V. Chobotov Ph.D., Chief Technology Officer (Age 56)
  • David M. Jennings, Vice President - Human Resources (Age 62)
  • Amanda L. DePalma, Vice President - Global Marketing (Age 45)
  • Meredith O. Huetter, Vice President - Global Medical Affairs (Age 43)
  • Michael P. Maszy, Vice President - Manufacturing (Age 40)

Who owns Endologix stock?

Endologix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Cortina Asset Management LLC (1.00%), Schwab Charles Investment Management Inc. (0.40%), California State Teachers Retirement System (0.16%), Wells Fargo & Company MN (0.13%), JPMorgan Chase & Co. (0.13%) and Valeo Financial Advisors LLC (0.04%). Company insiders that own Endologix stock include Amanda L Depalma, Charles Steele Love, Dan Lemaitre, Gregory D Waller, Guido J Neels, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Who sold Endologix stock? Who is selling Endologix stock?

Endologix's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and California State Teachers Retirement System. View Insider Buying and Selling for Endologix.

Who bought Endologix stock? Who is buying Endologix stock?

Endologix's stock was bought by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, JPMorgan Chase & Co., Valeo Financial Advisors LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy Endologix stock?

Shares of Endologix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of Endologix stock can currently be purchased for approximately $5.25.

How big of a company is Endologix?

Endologix has a market capitalization of $438.13 million and generates $192.93 million in revenue each year. The medical instruments supplier earns $-154,670,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Endologix employs 782 workers across the globe.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  307 (Vote Underperform)
Total Votes:  611
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endologix (NASDAQ:ELGX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.092.092.092.25
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.05$7.86$8.00$8.46
Price Target Upside: 22.18% upside62.64% upside83.91% upside81.12% upside

Endologix (NASDAQ:ELGX) Consensus Price Target History

Price Target History for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ:ELGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Piper Jaffray CompaniesReiterated RatingOverweight -> OverweightHighView Rating Details
11/8/2017Canaccord GenuityReiterated RatingHold$5.00N/AView Rating Details
11/8/2017Stifel NicolausLower Price TargetHold$6.00 -> $5.50N/AView Rating Details
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
8/3/2017OppenheimerSet Price TargetHold$5.00HighView Rating Details
5/18/2017BMO Capital MarketsReiterated RatingHold$5.00HighView Rating Details
5/18/2017StephensDowngradeOverweight -> Equal Weight$6.00HighView Rating Details
5/18/2017BTIG ResearchDowngradeBuy -> Neutral$7.00HighView Rating Details
12/7/2016Leerink SwannReiterated RatingMarket Perform$11.00 -> $8.00N/AView Rating Details
12/4/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$14.00 -> $10.00N/AView Rating Details
11/16/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
2/22/2016Credit Suisse GroupLower Price TargetOutperform$16.00 -> $10.00N/AView Rating Details
(Data available from 12/18/2015 forward)

Earnings

Endologix (NASDAQ:ELGX) Earnings History and Estimates Chart

Earnings by Quarter for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ ELGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018($0.20)N/AView Earnings Details
8/2/2017Q2 2017($0.18)($0.10)$47.58 million$48.60 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.24)($0.18)$41.15 million$42.60 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.19)($0.22)$48.69 million$47.46 millionViewListenView Earnings Details
11/1/2016Q316($0.15)($0.11)$51.83 million$52.12 millionViewN/AView Earnings Details
8/2/2016Q2($0.20)($0.20)$46.30 million$51.00 millionViewListenView Earnings Details
5/9/2016Q1($0.24)($0.25)$38.78 million$42.40 millionViewN/AView Earnings Details
2/22/2016Q4($0.16)($0.08)$39.97 million$39.20 millionViewListenView Earnings Details
10/26/2015Q315($0.14)($0.13)$38.12 million$38.20 millionViewListenView Earnings Details
8/3/2015Q215($0.13)($0.18)$39.47 million$39.50 millionViewN/AView Earnings Details
4/29/2015Q115($0.13)($0.14)$37.94 million$36.70 millionViewN/AView Earnings Details
2/25/2015Q414($0.10)($0.11)$38.10 million$38.80 millionViewN/AView Earnings Details
10/30/2014Q314($0.13)($0.13)$37.00 million$37.20 millionViewListenView Earnings Details
7/30/2014Q214($0.08)($0.06)$36.50 million$38.30 millionViewListenView Earnings Details
4/30/2014Q114($0.08)($0.08)$32.24 million$33.30 millionViewListenView Earnings Details
2/27/2014Q413($0.05)($0.05)$35.80 million$35.25 millionViewListenView Earnings Details
10/30/2013Q313($0.05)$0.01$32.47 million$33.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.06)($0.03)$33.94 million$34.00 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)($0.15)$29.26 million$29.80 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.03)($0.09)$29.03 million$29.22 millionViewN/AView Earnings Details
10/25/2012($0.04)($0.03)ViewN/AView Earnings Details
7/26/2012($0.04)($0.09)ViewN/AView Earnings Details
4/26/2012($0.06)($0.07)ViewN/AView Earnings Details
2/22/2012($0.05)($0.06)ViewN/AView Earnings Details
10/27/2011($0.05)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Endologix (NASDAQ:ELGX) Earnings Estimates

2017 EPS Consensus Estimate: ($0.74)
2018 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.22)($0.22)
Q2 20172($0.18)($0.16)($0.17)
Q3 20172($0.16)($0.15)($0.16)
Q4 20172($0.22)($0.17)($0.20)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endologix (NASDAQ:ELGX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Endologix (NASDAQ ELGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ ELGX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Dan LemaitreDirectorBuy22,522$4.43$99,772.46View SEC Filing  
5/19/2017Guido J NeelsDirectorBuy20,000$4.32$86,400.00View SEC Filing  
5/19/2017Robert D MitchellPresidentBuy2,200$4.32$9,504.00View SEC Filing  
12/14/2016John D McdermottCEOBuy10,000$6.67$66,700.00View SEC Filing  
12/14/2016Thomas F Zenty IIIDirectorBuy3,000$6.51$19,530.00View SEC Filing  
12/13/2016Vaseem MahboobCFOBuy20,000$6.25$125,000.00View SEC Filing  
11/18/2016Guido J NeelsDirectorBuy13,000$7.69$99,970.00View SEC Filing  
8/19/2016Jose A LimaVPSell4,710$11.68$55,012.80View SEC Filing  
8/5/2016Michael V ChobotovInsiderSell14,000$12.40$173,600.00View SEC Filing  
6/3/2016Gregory D WallerDirectorSell7,800$12.86$100,308.00View SEC Filing  
6/1/2016Amanda L DepalmaVPSell689$12.55$8,646.95View SEC Filing  
6/1/2016John D McdermottCEOSell6,116$12.55$76,755.80View SEC Filing  
6/1/2016Joseph A DejohnInsiderSell957$12.55$12,010.35View SEC Filing  
6/1/2016Robert D MitchellPresidentSell2,294$12.55$28,789.70View SEC Filing  
5/26/2016James Edward MachekVPSell6,500$12.76$82,940.00View SEC Filing  
1/26/2016Charles Steele LoveVPSell4,280$7.72$33,041.60View SEC Filing  
11/3/2015Guido J NeelsDirectorBuy11,000$9.32$102,520.00View SEC Filing  
11/3/2015Todd AbrahamVPBuy2,500$8.85$22,125.00View SEC Filing  
11/2/2015John D McdermottCEOBuy20,000$8.90$178,000.00View SEC Filing  
9/3/2015Jose A LimaVPSell1,923$12.60$24,229.80View SEC Filing  
5/26/2015Thomas WilderDirectorSell3,790$16.08$60,943.20View SEC Filing  
5/20/2015Jose A LimaVPSell1,872$16.75$31,356.00View SEC Filing  
4/6/2015Robert D MitchellPresidentSell45,000$17.33$779,850.00View SEC Filing  
12/12/2014Charles Steele LoveVPSell10,000$13.95$139,500.00View SEC Filing  
11/18/2014Charles Steele LoveVPBuy2,000$11.70$23,400.00View SEC Filing  
11/4/2014Guido J NeelsDirectorBuy10,000$11.21$112,100.00View SEC Filing  
11/4/2014John D McdermottCEOBuy25,000$11.25$281,250.00View SEC Filing  
8/4/2014Thomas WilderDirectorSell3,500$13.68$47,880.00View SEC Filing  
6/12/2014Robert D MitchellPresidentSell18,271$14.23$259,996.33View SEC Filing  
6/10/2014Robert D MitchellPresidentSell8,516$14.20$120,927.20View SEC Filing  
8/14/2013Stefan SchreckVPSell25,000$16.18$404,500.00View SEC Filing  
8/13/2013Stefan SchreckVPSell29,000$15.88$460,520.00View SEC Filing  
8/5/2013Gary SorsherVPSell12,483$15.98$199,478.34View SEC Filing  
8/5/2013John McdermottCEOSell165,000$16.00$2,640,000.00View SEC Filing  
8/2/2013Todd AbrahamVPSell9,994$15.90$158,904.60View SEC Filing  
8/1/2013John D McdermottCEOSell15,000$15.83$237,450.00View SEC Filing  
6/3/2013Thomas WilderDirectorSell22,500$13.25$298,125.00View SEC Filing  
5/28/2013Leonard M GreensteinVPSell1,253$14.01$17,554.53View SEC Filing  
12/28/2012Robert John KristCFOSell37,530$14.06$527,671.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endologix (NASDAQ ELGX) News Headlines

Source:
DateHeadline
Head to Head Review: Endologix (ELGX) versus Its RivalsHead to Head Review: Endologix (ELGX) versus Its Rivals
www.americanbankingnews.com - December 17 at 11:36 PM
Endologix (ELGX) versus The Competition Head to Head SurveyEndologix (ELGX) versus The Competition Head to Head Survey
www.americanbankingnews.com - December 17 at 9:28 PM
Endologix (ELGX) Downgraded to "Hold" at BidaskClubEndologix (ELGX) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - December 16 at 2:52 PM
ENDOLOGIX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ... - PR Newswire (press release)ENDOLOGIX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ... - PR Newswire (press release)
www.prnewswire.com - December 16 at 9:28 AM
Contrasting Endologix (ELGX) and The CompetitionContrasting Endologix (ELGX) and The Competition
www.americanbankingnews.com - December 15 at 3:30 PM
Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : December 15, 2017Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : December 15, 2017
finance.yahoo.com - December 15 at 9:51 AM
Analyzing Endologix (ELGX) & Its RivalsAnalyzing Endologix (ELGX) & Its Rivals
www.americanbankingnews.com - December 14 at 11:04 PM
Endologix (ELGX) vs. Its Peers Critical ContrastEndologix (ELGX) vs. Its Peers Critical Contrast
www.americanbankingnews.com - December 14 at 7:50 PM
Financial Comparison: Endologix (ELGX) vs. The CompetitionFinancial Comparison: Endologix (ELGX) vs. The Competition
www.americanbankingnews.com - December 14 at 5:30 AM
Reviewing Endologix (ELGX) & Its CompetitorsReviewing Endologix (ELGX) & Its Competitors
www.americanbankingnews.com - December 13 at 11:16 AM
Head-To-Head Contrast: Endologix (ELGX) and Its RivalsHead-To-Head Contrast: Endologix (ELGX) and Its Rivals
www.americanbankingnews.com - December 12 at 5:16 PM
Endologix (ELGX) Now Covered by Piper Jaffray CompaniesEndologix (ELGX) Now Covered by Piper Jaffray Companies
www.americanbankingnews.com - December 12 at 11:28 AM
Analyzing Endologix (ELGX) & The CompetitionAnalyzing Endologix (ELGX) & The Competition
www.americanbankingnews.com - December 12 at 7:57 AM
Financial Review: Endologix (ELGX) versus Its RivalsFinancial Review: Endologix (ELGX) versus Its Rivals
www.americanbankingnews.com - December 11 at 11:22 PM
Critical Comparison: Endologix (ELGX) vs. Its PeersCritical Comparison: Endologix (ELGX) vs. Its Peers
www.americanbankingnews.com - December 11 at 7:16 PM
$45.37 Million in Sales Expected for Endologix, Inc. (ELGX) This Quarter$45.37 Million in Sales Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - December 10 at 12:38 PM
Endologix (ELGX) vs. Its Rivals Critical SurveyEndologix (ELGX) vs. Its Rivals Critical Survey
www.americanbankingnews.com - December 8 at 7:46 PM
Endologix (ELGX) vs. Its Competitors Critical ComparisonEndologix (ELGX) vs. Its Competitors Critical Comparison
www.americanbankingnews.com - December 8 at 3:26 AM
ETFs with exposure to Endologix, Inc. : December 7, 2017ETFs with exposure to Endologix, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:49 PM
Comparing Endologix (ELGX) and Its PeersComparing Endologix (ELGX) and Its Peers
www.americanbankingnews.com - December 6 at 5:30 PM
Endologix, Inc. :ELGX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017Endologix, Inc. :ELGX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 10:08 AM
Analyzing Endologix (ELGX) and Its CompetitorsAnalyzing Endologix (ELGX) and Its Competitors
www.americanbankingnews.com - December 5 at 3:32 AM
ENDOLOGIX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates ... - Business Wire (press release)ENDOLOGIX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates ... - Business Wire (press release)
www.businesswire.com - December 2 at 5:11 PM
ENDOLOGIX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Endologix, Inc. - ELGXENDOLOGIX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Endologix, Inc. - ELGX
finance.yahoo.com - December 2 at 9:52 AM
Endologix, Inc. (ELGX) Given Average Recommendation of "Hold" by BrokeragesEndologix, Inc. (ELGX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 4:08 AM
Financial Survey: Endologix (ELGX) and Its RivalsFinancial Survey: Endologix (ELGX) and Its Rivals
www.americanbankingnews.com - November 26 at 11:06 PM
Zacks: Brokerages Anticipate Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.37 MillionZacks: Brokerages Anticipate Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.37 Million
www.americanbankingnews.com - November 22 at 4:28 AM
Endologix (ELGX) and Its Competitors Head to Head ComparisonEndologix (ELGX) and Its Competitors Head to Head Comparison
www.americanbankingnews.com - November 20 at 3:20 PM
Endologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare ConferenceEndologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare Conference
finance.yahoo.com - November 14 at 6:41 PM
Endologix, Inc. (ELGX) Short Interest UpdateEndologix, Inc. (ELGX) Short Interest Update
www.americanbankingnews.com - November 12 at 4:30 AM
Endologix, Inc. – Value Analysis (NASDAQ:ELGX) : November 10, 2017Endologix, Inc. – Value Analysis (NASDAQ:ELGX) : November 10, 2017
finance.yahoo.com - November 10 at 7:16 PM
Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : November 9, 2017Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : November 9, 2017
finance.yahoo.com - November 10 at 12:05 PM
Oppenheimer Holdings Equities Analysts Increase Earnings Estimates for Endologix, Inc. (ELGX)Oppenheimer Holdings Equities Analysts Increase Earnings Estimates for Endologix, Inc. (ELGX)
www.americanbankingnews.com - November 10 at 7:47 AM
Oppenheimer Holdings Equities Analysts Increase Earnings Estimates for Endologix, Inc. (ELGX)Oppenheimer Holdings Equities Analysts Increase Earnings Estimates for Endologix, Inc. (ELGX)
www.americanbankingnews.com - November 10 at 7:47 AM
Equities Analysts Set Expectations for Endologix, Inc.s FY2017 Earnings (ELGX)Equities Analysts Set Expectations for Endologix, Inc.'s FY2017 Earnings (ELGX)
www.americanbankingnews.com - November 10 at 7:47 AM
Endologix, Inc. (ELGX) Forecasted to Earn Q1 2018 Earnings of ($0.16) Per ShareEndologix, Inc. (ELGX) Forecasted to Earn Q1 2018 Earnings of ($0.16) Per Share
www.americanbankingnews.com - November 9 at 11:46 AM
Canaccord Genuity Reiterates Hold Rating for Endologix, Inc. (ELGX)Canaccord Genuity Reiterates Hold Rating for Endologix, Inc. (ELGX)
www.americanbankingnews.com - November 8 at 7:44 PM
NasdaqGS Healthcare Industry: A Deep Dive Into Endologix Inc (ELGX)NasdaqGS Healthcare Industry: A Deep Dive Into Endologix Inc (ELGX)
finance.yahoo.com - November 8 at 6:07 AM
Endologix, Inc. to Host Earnings CallEndologix, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 6:07 AM
Endologix Reports Third Quarter 2017 Financial ResultsEndologix Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 6:07 AM
Endologix reports 3Q lossEndologix reports 3Q loss
finance.yahoo.com - November 8 at 6:07 AM
Edited Transcript of ELGX earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of ELGX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 6:07 AM
ELGX Crosses Above Average Analyst TargetELGX Crosses Above Average Analyst Target
www.thestreet.com - November 6 at 7:43 PM
Endologix, Inc. (ELGX) Receives Consensus Rating of "Hold" from BrokeragesEndologix, Inc. (ELGX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 1:32 AM
Obalon Therptcs (OBLN) vs. Endologix (ELGX) Head-To-Head SurveyObalon Therptcs (OBLN) vs. Endologix (ELGX) Head-To-Head Survey
www.americanbankingnews.com - November 2 at 9:38 PM
Zacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $47.21 MillionZacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $47.21 Million
www.americanbankingnews.com - November 2 at 11:02 AM
Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - November 2 at 12:19 AM
Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - November 1 at 7:19 PM
Endologix, Inc. (ELGX) Set to Announce Quarterly Earnings on TuesdayEndologix, Inc. (ELGX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 11:34 AM
Is Endologix Inc (ELGX) A Financially Sound Company?Is Endologix Inc (ELGX) A Financially Sound Company?
finance.yahoo.com - October 30 at 6:56 PM

SEC Filings

Endologix (NASDAQ:ELGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endologix (NASDAQ:ELGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endologix (NASDAQ ELGX) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.